4//SEC Filing
Takeda Ventures, Inc. 4
Accession 0001209191-19-029480
CIK 0001662774other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 7:52 PM ET
Size
15.2 KB
Accession
0001209191-19-029480
Insider Transaction Report
Form 4
Cortexyme, Inc.CRTX
Takeda Pharmaceuticals U.S.A., Inc.
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+2,679,802→ 2,679,802 total - Conversion
Series A Redeemable Convertible Preferred Stock
2019-05-13−2,360,071→ 0 total→ Common Stock (2,360,071 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−319,731→ 0 total→ Common Stock (319,731 underlying)
Takeda Ventures, Inc.
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+2,679,802→ 2,679,802 total - Conversion
Series A Redeemable Convertible Preferred Stock
2019-05-13−2,360,071→ 0 total→ Common Stock (2,360,071 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−319,731→ 0 total→ Common Stock (319,731 underlying)
TAKEDA PHARMACEUTICAL CO LTD
10% Owner
Transactions
- Conversion
Common Stock
2019-05-13+2,679,802→ 2,679,802 total - Conversion
Series A Redeemable Convertible Preferred Stock
2019-05-13−2,360,071→ 0 total→ Common Stock (2,360,071 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−319,731→ 0 total→ Common Stock (319,731 underlying)
Transactions
- Conversion
Common Stock
2019-05-13+2,679,802→ 2,679,802 total - Conversion
Series A Redeemable Convertible Preferred Stock
2019-05-13−2,360,071→ 0 total→ Common Stock (2,360,071 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2019-05-13−319,731→ 0 total→ Common Stock (319,731 underlying)
Footnotes (3)
- [F1]The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.
- [F2]Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.
- [F3]These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.
Documents
Issuer
Cortexyme, Inc.
CIK 0001662774
Entity typeother
Related Parties
1- filerCIK 0001771657
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 7:52 PM ET
- Size
- 15.2 KB